The American pharmaceutical group Eli Lilly published Thursday the results of a new clinical trial confirming that its molecule tirzepatide, currently approved in the United States against diabetes, is effective. The results pave the way for a possible upcoming authorization of this drug by the US Drug Administration (FDA) for obese people specifically.
The study was conducted on just over 900 overweight or obese participants with type 2 diabetes (the most common) The drug is taken once a week in the form of an injection and people given the highest dosage lost an average of 15.6 pounds over about one and a half years.